GeneDx (WGS) Q2 FY26 earnings call

GeneDx delivered a solid Q2 FY26 with record test volumes and an earlier-than-expected return to profitability, driven by strong demand and completed cost actions. The company is now intensely focused on optimizing unit economics and improving collection rates, particularly for genome testing, which saw significant payer coverage expansion. Management expects meaningful improvements in collection rates and cash flow generation in Q4 FY26 and 2027.